Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
The MMRF Names New Organizational Leadership
Michael Andreini appointed President & CEO; Anne Quinn Young to serve as Brand President; Karen Dietz named General Counsel & Chief Administrative Officer
Norwalk, CT, January 20, 2021 – The Multiple Myeloma Research Foundation (MMRF) has strengthened its position as a leading cancer research organization with new appointments to its executive leadership. Michael Andreini, who previously served as Chief Operating Officer, has been named President and Chief Executive Officer. Chief Marketing and Development Officer Anne Quinn Young, MPH, has been promoted to Brand President. In addition, Karen Dietz, JD, MBA, will expand her role as the MMRF’s General Counsel and Chief Administrative Officer.
“The breadth and depth of experience each member of the MMRF leadership team brings to the organization is world-class. They all possess a deep-rooted commitment to our mission and have played critical roles in positioning the MMRF for continued success,” said Kathy Giusti, Founder and Chief Mission Officer of the MMRF. “The MMRF is a leader in cancer research because of the tireless work of stakeholders, partners, and staff. As we look to the future, we will continue to drive forward the innovative work that is bringing us closer to curing myeloma every day.”
Mr. Andreini joined the MMRF as Chief Operating Officer in 2019. In that role, he built a strong record working with Ms. Giusti to develop the MMRF’s current strategic plan in addition to leading its execution, as well as forging alliances across the organization and multiple myeloma community. Mr. Andreini’s prior experience includes work in the strategy and management consulting industry at IQVIA, where he developed strategies for biopharma, medical device, and non-profit organizations to drive innovation and operational excellence across a diverse set of business challenges. Mr. Andreini earned a B.A. in chemistry with a minor concentration in economics from Colgate University.
Mr. Andreini takes the reins from Paul Giusti, who is stepping down after serving nearly five years as President and CEO of the MMRF. During his tenure, Mr. Giusti spearheaded the MMRF’s pioneering work in accelerating new immunotherapies through the clinical pipeline, launching the first myeloma-focused venture philanthropy fund, and generating valuable multiple myeloma data to answer the most pressing patient questions. Most recently, the MMRF launched CureCloud, a first-of-its-kind research study, that collects genomic and clinical information from multiple myeloma patients through at-home testing.
In addition to Mr. Andreini’s new role, the MMRF has announced the appointment of Chief Marketing and Development Officer Anne Quinn Young, MPH, to the newly created position of Brand President. An 18-year veteran of the organization, Ms. Young will continue to champion the MMRF’s mission as the steadfast voice of multiple myeloma patients, while also focusing on building and strengthening strategic partnerships and its external presence. Karen Dietz, JD, MBA, a 13-year veteran of the MMRF, who manages corporate governance, contract negotiations, compliance, and intellectual property, will expand her role within the organization overseeing its human resources department as General Counsel and Chief Administrative Officer. The MMRF Founder, Kathy Giusti, will continue to serve as Chief Mission Officer of the organization.
New members join the MMRF and Myeloma Investment Fund (MIF) Boards of Directors
The MMRF and its subsidiary, the Myeloma Investment Fund (MIF), have also named two new members to each organizations’ Board of Directors. Adrian Rosenkranz, Chief Operating Officer of Salesforce Essentials, has joined the MMRF Board of Directors; and Hugh Martin, President and CEO of Lacuna Technologies Inc., will now serve as the Chair of MIF’s Board of Directors.
“I am humbled to take on the role of President and CEO of the MMRF and look forward to build upon its legacy alongside our Board partners, leadership team, and staff,” said Mr. Andreini. “As the MMRF embarks on a new chapter, we stay committed to the patients and families we serve as we pursue better treatments and more equitable access to care for the entire myeloma patient community. With great urgency and optimism, we will drive even closer to our goal of a world without multiple myeloma.”
About the Multiple Myeloma Research Foundation (MMRF) A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 13 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immune-oncology, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
